Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
Research ArticleTechnology/Application

Validation of the BacT/ALERT® 3D System for Rapid Sterility Testing of Biopharmaceutical Samples

Luis Jimenez, Narendra Rana, Joseph Amalraj, Kimberly Walker and Kasey Travers
PDA Journal of Pharmaceutical Science and Technology January 2012, 66 (1) 38-54; DOI: https://doi.org/10.5731/pdajpst.2012.00790
Luis Jimenez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: papojbmicro@gmail.com
Narendra Rana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Amalraj
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly Walker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kasey Travers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Abstract

The BacT/ALERT® 3D system was validated to determine the sterility of different types of biopharmaceutical samples such as water for injection, unprocessed bulk, and finished bulk. The installation, operation, and performance qualification were completed and verified under good manufacturing practices. During the installation and operation validation stages, the functionality and security of the system and software were completed and verified. For the performance qualification, 11 microorganisms were evaluated, six compendial (Pseudomonas aeruginosa, Staphylococcus aureus, Bacillus subtilis, Candida albicans, Aspergillus niger, Clostridium sporogenes), one representing the number one microbial species in sterile product recalls (Burkholderia cepacia), and four environmental isolates (Kocuria rhizophila, Staphylococcus haemolyticus, Methylobacterium radiotolerans, and Penicillium spp.). Nine of the microorganisms were spiked into three different types of biopharmaceutical samples by three different analysts on different days to ascertain the equivalence, ruggedness, sensitivity, time of detection, and repeatability. In all samples, the BacT/ALERT® exhibited equivalent or better detection than the standard test. With the exception of M. radiotolerans, all 11 microorganisms were detected within 2.5 days using the BacT/ALERT® system and the standard test. The detection times for M. radiotolerans in the three sample types averaged 5.77 days. The minimum detectable level of cells for all the microorganisms tested was found to be within 1 to 2 CFU. The system optimized sterility testing by the simultaneous on-line, non-destructive incubation and detection of microbial growth.

Introduction

Compendial sterility testing of biopharmaceutical products is based upon the addition of aliquots or membranes with the concentrated samples to different types of media (1, 2). One of the media is specific for aerobic microorganisms and the other selectively enriches for anaerobic microorganisms. The standard incubation time for both media is 14 days. Different temperatures are used for aerobic (25 °C) and anaerobic (35 °C) microorganisms. Positive microbial growth is defined by the development of turbidity in the enrichment media. The test is cumbersome and requires special gowning procedures, equipment, and laboratory facilities to reduce the risk of analyst's and environmental contamination during testing. Sample incubation after testing requires specific incubators and daily visual readings of the enrichment cultures by the analyst to document the results. Visual readings are extremely subjective; when slow microbial growth is present, a slight pellicle can form at the bottom of the test tube or canister and will not be seen unless the sample is moderately shaken. Furthermore, in some cases when the enrichments are turbid upon the addition of samples, it's very hard to ascertain the presence or absence of microbial growth after incubation (3, 4). Therefore, samples must be streaked onto solid agar media to determine the presence of any viable and culturable microorganism. This additional step extends the completion time for the test.

Different technologies have been reported for the rapid testing of sterile pharmaceutical products (5–8). Previous studies performed utilized adenosine 5′-triphosphate (ATP) bioluminescence and polymerase chain reaction (PCR) analysis using universal bacterial sequences for the testing of liquid products (4, 8). Recent studies demonstrated the evaluation of ATP bioluminescence and solid phase laser scanning cytometry to determine the sterility of filterable aqueous solutions (5–7). All these studies were based upon the retrieval of an aliquot from the sample container and subsequent manipulation by adding reagents and/or other materials to determine the presence or absence of microbial growth or genetic sequences. Furthermore, after the analyses were completed, the assay's signal was detected in a reader of either bioluminescence or fluorescence. None of the systems provided for the on-line monitoring of the incubated sample on a continuous basis without further manipulations of the sample. This manipulation creates a potential risk for microbial contamination by the analyst.

A non-invasive and continuous on-line monitoring of the inoculated sample will provide real-time monitoring of sample's quality. The BacT/ALERT® 3D system detects the generation of carbon dioxide by microorganisms in a sample by a non-invasive technology. After sample addition to the enrichment media, analysis occurs continuously and without any retrieval of aliquots from the system. Previous studies demonstrated the use of the system to determine the sterility of cell therapy products (9). The sterility testing of autologous cultured chondrocytes was successfully validated by demonstrating the recovery of inoculated microorganisms (9). The study demonstrated the feasibility of the system to continuously detect the contamination by bacteria, yeast, and mold. However, no studies have been performed on the use of the system for the sterility testing of biopharmaceutical samples.

The major objective of this study was to ascertain the functionality of the BacT/ALERT® 3D system to analyze the sterility of different types of biopharmaceutical samples through the processing stages of producing a finished product and to complete and verify the installation, operation, and performance qualification of the system under good manufacturing practices (GMPs).

Materials and Methods

System Description

The BacT/ALERT® 3D System is a fully automated microbial detection system manufactured by bioMerieux (Saint Louis, MO). It incubates, agitates, and with solid state reflectometers continuously monitors the status of each culture bottle for microbial growth. It includes a control module and an incubator module (Figure 1). The control module has dimensions of 14″ wide × 36″ high × 24.3″ deep and weighs 91 pounds. The incubator module has dimensions of 19.5″ wide × 36″ high × 24.3″ deep and weighs 262 pounds. The incubator module can hold up to 240 bottles at a time. Additionally, five more incubator modules can be added to the system, if required. The operating range of the incubator is 25–45 °C. The control module has a barcode scanner for scanning culture bottle labels and identifying the bottle when loading and unloading. An interactive touch screen on the control module allows the operator to control and monitor the incubator module.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

BacT/ALERT® control module and incubation module.

The BacT/ALERT® 3D system is connected directly to a data management computer, where data generated by the instrument is managed by a data management software called OBSERVA®. The software is installed in a computer system (BacT/ALERT® workstation) with Microsoft Windows XP Professional (Figure 2). The OBSERVA® software provides the ability to configure the user interface, data fields, and reports to meet specific needs. It provides high levels of security by logging system activities to ensure that data integrity and change histories are maintained. The OBSERVA® can be used to generate reports, graph bottle readings, view product information and test results, store data, and keep information/data secure using system access levels, user accounts, and user passwords. A separate barcode scanner is attached to the computer system. In addition, there is a standard sized, 101 key keyboard. This is used as an additional input device to both the touch screen and barcode scanner. In case of power loss, there is an external uninterruptible power supply (UPS) that provides battery backup power to the computer system and instrument. The instrument also has an inbuilt UPS to provide a backup power for 1 min in case of voltage fluctuation. An external 56 k fax modem (controlled with an on/off switch) provides remote access for diagnostics and trouble shooting by bioMerieux personnel, if required.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

OBSERVA® computer software station.

The BacT/ALERT® 3D system utilizes a colorimetric sensor and reflected light to determine the amount of carbon dioxide (CO2) that is dissolved in the culture medium. If microorganisms are present in the test sample, CO2 is produced as the organisms metabolize the substrates in the culture medium. When growth of the microorganisms produces CO2, the color of the sensor in the bottom of each culture bottle changes and the light is reflected to the sensor. This information is transmitted to the computer, where it is compared to the initial CO2 level in the bottle. The sample is determined positive based on the rate of CO2 production. If after a specified number of days the CO2 level does not change significantly, the sample is determined negative. Cells are scanned with data points graphed every 10 min. Each sample has its own baseline reading and is monitored unique unto itself. The system is non-invasive and non-destructive. A touch-activated operator panel allows for a text-free user interface to direct loading and unloading of individual test samples. Once placed in the unit, handling of a specimen/sample bottle is not required until a result is obtained. Immediately upon detection, positive results are indicated visually on the unit's monitor and, if desired, by an audible beep. If no microbial growth is present after a specified time, a specimen/sample is determined to be negative. The system will also indicate the negative samples that are ready for removal when prompted. Because the system handles bottles individually, testing of new specimens/samples may begin at any time. The system also utilizes barcode technology to assist in specimen/sample and data tracking. The BacT/ALERT® system and the OBSERVA® software are compliant with 21 CFR Part 11 (10). A user name and password is required to access all functions available. The computer is connected to a remote GMP server located in the server room. All the test results generated will be saved to the local hard drive with encrypted database format. The system has the ability to program security access levels. All the data are manually transferred to the GMP server. A pre-customized report can be printed from the printer when needed. A CDRW (compact disc–rewriteable) drive is located on the control module for system backup and software upgrades. The system allows the user to perform automatic and manual data back-up, if required. The system comes equipped with error messaging and automatically records and stores every error message.

Installation Qualification

The installation qualification covered the following: System Documentation Verification, Equipment/Component List, Instrument Calibration Verification, Utility Verification, Software Verification and Installation, and Environmental Condition Verification (Table I). A calibrated multimeter (Fluke 177 True RMS, Everett, WA) was used to verify that the required utilities such as power outlets were within specifications as defined by the operating manuals.

View this table:
  • View inline
  • View popup
TABLE I

Installation Qualification Test Results

Operation Qualification

The operation qualification was initiated by drafting and collecting all operating procedures used during the installation and operation qualification (Table II). The Operation Qualification of the system verified and documented the functionality of the operational parameter as specified in the user requirements. The operation qualification testing included the following: OBSERVA® Software Security Level Verification, OBSERVA® Software Screen Navigation Verification, OBSERVA® Software Configuration, Verification, OBSERVA® Software Access Level Verification, BacT/ALERT Workstation Security Verification, Barcode Scanner Verification at BacT/ALERT Workstation, BacT/ALERT Instrument Security Verification, BacT/ALERT Instrument Alarm Verification, Power Loss/Equipment Failure Test, BacT/ALERT Instrument Screen Navigation Verification, Barcode Scanner Verification at BacT/ALERT Instrument, System Function Verification, Report Logged Temperature Verification, Enable/Disable Cells, Racks, Drawers Verification, Data Backup Verification, Temperature Calibration Verification, Cell Calibration Verification, Audit Trail Verification, Archived Report Verification, Empty Chamber Temperature Distribution Study, and Loaded Chamber Temperature Penetration Study (Table II).

View this table:
  • View inline
  • View popup
TABLE II

Operation Qualification Test Results

Performance Qualification

Samples:

There were four different types of samples analyzed during the performance qualification of the system. These samples were sterile water for injection (sWFI), unprocessed bulk (UB), finished bulk (FB), and finished biopharmaceutical product (FBP).

Microorganisms:

Table III shows the different types of microorganisms used during the validation studies. Samples of sWFI, UB, and FB were spiked with 11 different types of microorganisms. The microorganisms spiked were Pseudomonas aeruginosa ATCC 9027, Staphylococcus aureus ATCC 6538, Bacillus subtilis ATCC 6633, Candida albicans ATCC 10231, Aspergillus niger ATCC 16404. Burkholderia cepacia ATCC 26144, Clostridium sporogenes ATCC 11437, Kocuria rhizophila (environmental isolate), Staphylococcus haemolyticus (environmental isolate), Methylobacterium radiotolerans (environmental isolate), and Penicillium species (environmental isolate). All the microbial identifications were confirmed by 16S rRNA sequencing performed at Accugenix Inc. (Newark, DE).

View this table:
  • View inline
  • View popup
TABLE III

Challenge Microorganisms

Inoculation Preparation:

Different aliquots of the sWFI (10 mL), UB (5 mL), and FB (5 mL) samples were added to regular tryptic soy broth (TSB), regular fluid thioglycollate medium (FTM), BacT/ALERT® bottle iFA (aerobic) media, and BacT/ALERT® bottle iFN (anaerobic) media. After sample addition, all media were inoculated with the target inoculum. The first six microorganisms from Table III were rehydrated using the Bioballs (bioMerieux) to get an inoculum of less than 100 colony-forming units (CFU) for the sensitivity, repeatability, time of detection, and ruggedness studies, and close to 1 CFU for the limits of detection studies.

Two environmental bacterial isolates classified as K. rhizophila and S. haemolyticus were grown in TSB for 72 h at 30–35 °C. An environmental mold isolate classified as Penicillium spp. was grown in TSB for 72 h at 20–25 °C. B. cepacia was grown from the KWIK-STIK™ Plus system (Microbiologics, Saint Cloud, MN) and incubated into TSB and grown for 48 h at 30–35 °C. After the above incubations were completed, serial dilutions of the microorganisms were performed to achieve an inoculum of less than 100 CFU. The Clostridium sporogenes inoculum was confirmed by plating on Schaedler Blood Agar OxyPlates. The rest of the microorganisms were plated on tryptic soy agar (TSA) media. All the plates were incubated for a minimum of 5 days at 30–35 °C. Methylobacterium radiotolerans was grown on a Supor® Membrane (Pall Life Sciences, Ann Arbor, MI) placed on R2A media for 7 days at 30–35 °C. After incubation, the microbial growth was harvested from the membrane with four sterile inoculation loops and suspended in sterile phosphate-buffered saline (sPBS). Serial dilutions in sPBS were performed to achieve an inoculum of less than 100 CFU for the sWFI, UB, and FB studies between analysts and close to 1 CFU for the limits of detection studies. Inoculum plates were incubated as described above and read after 7 days.

Equivalence (with Microorganisms Spiked), Sensitivity, Repeatability, Limits of Detection, Time of Detection, and Ruggedness (Table IV):

For each sample of sWFI, UB, and FB, three different analysts added aliquots to iFA and regular TSB bottles for aerobic bacteria and iFN and regular FTM bottles for anaerobic bacteria. The iFA and iFN bottles are modified TSB and FTM media with activated charcoal (bioMerieux). After sample addition, aliquots of the first nine microorganisms from Table III were added to all bottles. Each microorganism was added to media bottles without any sample as a positive growth control. The iFA and iFN bottles were loaded into the system and incubated for 14 days at 33 °C. The regular TSB and FTM bottles were incubated at 25 °C and 35 °C for 14 days, respectively (1, 2). Samples were visually observed daily until a visual endpoint was determined to be positive.

View this table:
  • View inline
  • View popup
TABLE IV

Performance Qualification Criteria

Limits of Detection Studies:

For the limits of detection studies, aliquots of different microorganisms were diluted into sPBS to achieve approximately a 1 CFU per inoculum. After dilution, the microbial suspensions were inoculated into the BacT/ALERT bottles containing 5 mL of a biopharmaceutical, for example, UB or FB. The inoculum counts were verified by plating the aliquots as described above.

Equivalence without Microorganisms Spiked:

For each sample belonging to the sWFI, UB, and FB group, the traditional sterility test using the Steritest™ system (11) and the BacT/ALERT® system were performed in triplicates.

Validation Test:

Three different lot numbers of two types of FBPs were tested to determine the bacteriostasis and fungistasis of the different formulations. An aliquot of 5 mL of each product was added to either iFA or iFN media. An inoculum of not more than 100 CFU of the first six microorganisms listed on Table I was spiked into the sample containers as per USP and EP requirements (1, 2). A positive control of each microorganism inoculated in the media was also analyzed. The samples were loaded into the BacT/ALERT® system and incubated for 5 days at 33 °C.

Results and Discussions

Because of the importance of sterility testing to determine the safety of pharmaceutical and biopharmaceutical products, an alternative method protocol and validation study must be thorough and reproducible. Several studies have reported the validation of alternative microbiological methods for the analysis of sterile pharmaceutical products (6, 7, 9). These studies were based upon the recovery of microorganisms from samples using different types of assays and detection systems. Specific regulatory informational chapters described the recommended parameters needed to demonstrate the suitability of an alternative microbiological system for sterility testing (12–14).

The BacT/ALERT® is a multi-component system based upon a control and incubator module connected to a database to manage and control the information generated by the system. Therefore, the first step in the validation of the system was the installation qualification to verify the manufacturer's specifications and procedures. The actual installation was visually observed and inspected to verify that it agrees with the system documentation.

The installation qualification of the BacT/ALERT® system was initiated by the collection and verification of all related documents supplied by the vendor. These documents were the BacT/ALERT® user guide and certificate of calibration. A list of specifications, manuals, standard operating procedures (SOPs), reports, and certifications associated with the system was completed and verified (Table I). An equipment component list based upon information from nameplate, manufacturer name, model number, calibration date, purchase orders, serial numbers, and descriptions of each component was completed and verified.

All calibrations were verified to be in compliance with National Institute of Standards and Technology (NIST) standards. Recalibration intervals for critical instrumentation were established to be yearly. All information regarding the manufacturer name, serial numbers, utility verification, and software verification was documented and verified (Table I). The installation of the system and the software were successfully completed and verified based upon the manufacturer's specifications (Table I).

The operation qualification was initiated by the development of a SOP specifically written for the operation, maintenance, and documentation of the system (Table II). This SOP covered not only these areas but also the back-up of archived reports, instrument data, operating software, user access, and audit trails. All the analysts were assigned confidential user names and passwords to access the different levels of the system to establish a secure and stable operational environment. The configuration of the system's software was determined to maximize efficiency and protect data integrity (10). The original access levels created were based upon the ability of an analyst to load samples into the instruments and generating the final reports. However, the software did not have the capability of protecting the data integrity from manipulations from the analysts who loaded the samples. Therefore, a segregation of user access allowed the protection of the data integrity by restricting the analyst to loading the samples and entering the test parameters and sample information. Once the test was initiated, the same analyst cannot generate the final report nor has any access to modify the report. A different analyst who did not load the samples into the system was capable of the report generation. Furthermore, because all analysts have a specific access to the system by passwords and user name, the system's data trail allowed the constant audit of analyst's behavior preventing the possibility of data manipulation. All the alarms system incorporated into the system such as Power/Loss and System Function were verified and found to be functional (Table II). Similar results were obtained with all the other parameters described in Table II.

Because the system is based upon the continuous incubation and reading of the samples, it was very important to map the incubator chambers to determine the stability of the set temperature. Empty and full chambers temperature measurements were performed to determine the stability of the set point temperature. The chosen temperature for sample's incubation was determined to be 33 °C. Preliminary studies demonstrated that this temperature allowed the optimal growth of bacteria, yeast, and mold both for clinical and environmental isolates. Temperature readings were stable over a 24 h period under continuous operation for both empty and full chamber runs. Furthermore, ongoing, daily use of the system confirmed the stability of the set point temperature. A range of Embedded Image0.5 °C was chosen for the set point temperature. A SOP was established to recalibrate the temperature if an out-of-range reading was recorded.

To determine that the WFI, UB, and FB samples did not interfere with the detection platform of the system by generating background CO2 enough to trigger a false positive result, aliquots of the three different sample types were added into iFA (aerobic) and iFN (anaerobic) media. The bottles were incubated for 14 days. Table V shows the incubation of the biopharmaceutical samples inoculated into the media used for sterility testing with the BacT/ALERT®. No CO2 production was detected by any of the samples, indicating the absence of microbial growth. Furthermore, during the spiking studies additional negative samples were also incubated. A positive result was never obtained. This demonstrated that the samples did not have any interference with the assay and that there was no CO2 generated by the different cell culture and purification materials.

View this table:
  • View inline
  • View popup
TABLE V

Data Obtained from Inoculating Aerobic and Anaerobic Bottles with WFI, Unprocessed Bulk, and Finished Bulk Samples

The performance qualification experiments were designed to comply with the requirements described by the published pharmacopeial chapters and guidelines on the validation of alternative microbiological methods (Table IV) (12–14). Similar protocols were previously reported for the validation of the system to detect microbial contamination in cell therapy products (9). The protocol evaluated the system for sensitivity, limits of detection, ruggedness, equivalency with and without microbial spiking, time of detection, and repeatability (Table IV). Eleven different microbial species were used in this study (Table III). In addition to the compendial strains recommended by the regulatory agencies, Burkholderia cepacia was part of the study due its frequent presence in sterile product recalls (15). Previous studies reported that B. cepacia is the most frequently isolated microbial species in sterile product recalls (15). Four environmental isolates identified as Kocuria rhizophila, Staphylococcus haemolyticus, Methylobacterium radiotolerans, and Penicillium spp. were also spiked into individual samples. Of these four microbial species, M. radiotolerans exhibited the slower growth at either 25, 33, or 35 °C. The first nine microorganisms from Table III were spiked into the samples by three different analysts, while B. cepacia and M. radiotorerans studies were performed by a single analyst in triplicates and analyzed using the BacT/ALERT® 3D system.

The manufacturing of biopharmaceutical products comprises the processing of mammalian cell cultures in a bioreactor to produce the maximum quantities of drug product (16). All reagents and raw materials are thoroughly tested for the presence of microorganisms. Water is a very important raw material that is used in the processing and rinsing of materials and equipment. The performance qualification of the system was initiated by the three analysts inoculating aliquots of nine different types of microorganisms to samples of 10 mL of sWFI with an inoculum level of less than 100 CFU. The samples were tested using the standard sterility test by using TSB and FTM media and the BacT/ALERT® system with iFA (aerobic) and iFN (anaerobic) media. Additional studies were also performed in triplicate with a single analyst spiking B. cepacia and M. radiotolerans into the iFA and iFN media bottles containing sWFI samples.

The sensitivity, ruggedness, repeatability, and time of detection of the system were demonstrated by detecting all nine microorganisms in the water samples by the three analysts. Both the BacT/ALERT® system and the standard method were able to detect all the bacteria, yeast, and mold spiked into the samples within 14 days of incubation (Table VI). All anaerobic and aerobic microorganisms were also detected using the two different types of growth media. The limits of detection between the three analysts in sWFI samples were ranging from a low of 3 CFU by K. rhizophila to a high of 67 CFU by Penicillium sp. (Table VII). These limits of detection represent the lowest and highest CFU per plate obtained by any of the three analysts during the inoculation studies.

View this table:
  • View inline
  • View popup
TABLE VI

Detection of Microorganisms in Biopharmaceutical Samples Using the BacT/ALERT® by Three Different Analysts

View this table:
  • View inline
  • View popup
TABLE VII

Mean Limit of Detection of Different Biopharmaceutical Samples

Both microbes were environmental isolates from different cleanroom sampling sites. K. rhizophila exhibited a slow growth rate when grown in regular TSB media at 25 °C, and detection time was 3 days; but it was detected by the BacT/ALERT® system within 1.57 days at 33 °C (Figure 3). Evidently, higher incubation temperatures and shaking accelerated the growth of K. rhizophila, allowing the faster detection by the BacT/ALERT® system.

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

Detection of microorganisms by the BacT/ALERT® (BacT) and standard method (SM) in three different biopharmaceutical samples.

The ruggedness of the system was proven to be strong, as all the microorganisms were detected by different analysts on different days using different reagents and inoculum preparations. Time to detection for all microorganisms was faster with the BacT/ALERT®. Furthermore, the average detection time for all microorganisms in water by all three analysts was 1.16 days, while the average detection time using the standard method media was 2.4 days (Table VI, Figure 3). The fastest detection time by the BacT/ALERT® was observed by B. subtilis with 0.64 days, while A. niger showed the longest with 1.87 days (Table VI). The BacT/ALERT® was found to be equivalent to the standard method because both detected all microorganisms within 3 days (Figure 3). However, the higher incubation temperature and agitation of the samples in the BacT/ALERT® system accelerated the growth of all the microorganisms analyzed, decreasing the time of detection. The longest overall detection time in sWFI samples was obtained with M. radiotolerans. A single analyst study performed in triplicate showed an average detection time of 4.31 days.

Equivalency was also determined by analyzing unspiked samples with the BacT/ALERT® and the Steritest™ system. All the nine samples representing triplicate samples of the sWFI, UB, and FB categories were found to be negative by both methods (Table VIII). Furthermore, the Steritest™ testing was performed in a different facility and with different analysts. For repeatability, all replicates inoculated with microorganisms either using the BacT/ALERT® or standard media were positives as determined by the three different analysts (Figure 3).

View this table:
  • View inline
  • View popup
TABLE VIII

Equivalent Testing of Uninoculated Biopharmaceutical Sample A Using the BacT/ALERT® and the Steritest System

In the biopharmaceutical industry, downstream processing is a series of operations that starts with a large volume of a complex biological mixture and refines it to a small volume containing the purified product in bulk form (16). Once the mammalian cells in the bioreactor reached the density and activity required for optimal antibody production, the cells are harvested to separate them from the protein fraction. This is what is called UB. The UB samples were spiked with nine different microorganisms by the three analysts and B. cepacia and M. radiotolerans in triplicate by a single analyst. The limits of detection between the three analysts in UB ranged from a low of 4 CFU by S. haemolyticus and Penicillium spp. to a high of 67 CFU by C. albicans (Table VII). All microorganisms were detected by the three analysts within 14 days. The average detection time with the BacT/ALERT® for all microorganisms in UB as determined by all three analysts was 1.25 days. The fastest detection time was observed again by B. subtilis with 0.66 days, while C. albicans showed the longest with 2.91 days (Table VI). In the UB samples, the BacT/ALERT® was equivalent to the standard enrichment method. Similar to the sWFI samples, the longest detection time in the UB was found to be 6.24 days by M. radiotolerans.

After the antibody is purified out from the mixture, the FB drug goes into final processing formulation (16). For the FB samples, the limits of detection between the three analysts ranged from 1 CFU by C. albicans to 56 CFU by both C. sporogenes and S. aureus (Table VII). For the FB samples, the average detection time for all microorganisms by all three analysts using the BacT/ALERT® was 1.23 days. The fastest detection time was observed by B. subtilis with 0.65 days, while C. albicans showed the longest with 2.47 days (Table VI). Again in the FB samples, the BacT/ALERT® was equivalent to the standard enrichment method. The longest detection time in the FB samples was found to be 6.50 days by M. radiotolerans.

The BacT/ALERT® system always detected all the microorganisms faster than the standard method (Figure 3). Although a single incubation temperature, for example, 33 °C, was used, there was no negative impact on the sensitivity of the assay. All microorganisms were detected in the three different sample types analyzed. The system also agitated the samples, which was completely different from the static cultures used in the compendial tests (1, 2). Evidently, this sample agitation enhanced the detection of the microorganisms by the system. These results confirmed the studies reported by previous investigators using different biological samples such as autologous cultured chondrocytes (9).

To determine the minimum levels of microorganisms detected by the system, different microorganisms were diluted in sPBS to achieve and inoculum of 1 CFU and immediately spiked into the biopharmaceutical samples. Dilutions were made to try to get to a 1 CFU inoculum, which was obtained, in some cases but overall all the microorganisms spiked into different biopharmaceutical products were detected within a limit of 1–2 CFU (Table IX). All microorganisms were detected in less than 7 days regardless of the inoculum level spiked (Table IX). For example, P. aeruginosa was inoculated at three different inoculum levels, 23 CFU, 2 CFU, and 1 CFU. However, after incubation, the conditions were optimal enough to detect all the different inoculation levels within 1 day. On the other hand, M. radiotolerans inoculated with 12 CFU and 2 CFU was detected within 7 days. For all the microorganisms tested the enrichment conditions were favorable enough for the cells to multiply and provide a positive signal. The system is a rapid absence/presence test and does not provide quantitative information. Previous studies reported estimated limits of detection for the BacT/ALERT® 3D of 1–2 CFU in antibiotics formulations artificially contaminated using the most probable limit of detection method (17). We were able to verify these results with artificially contaminated biopharmaceutical samples. The use of enrichment procedures optimizing the detection of microbial contamination in pharmaceutical samples using the BacT/ALERT® 3D and ATP bioluminescence assays have been previously demonstrated (17, 18). The iFA and iFN growth media used in this study are basically the same used for the standard sterility test, TSB and FTM. However, the iFA and iFN media were modified by the addition of activated charcoal to neutralize the antimicrobial activity of a given formulation (9). The standard sterility test relies on visual endpoints, which are extremely subjective and create false readings in turbid samples or in samples with low turbidity (4). For instance, microorganisms with slow growth rate and low biomass such as M. radiotolerans and K. rhizophila do not produce high microbial biomass in enrichment broths during standard tests. However, the BacT/ALERT® 3D detection technology is based upon the production of carbon dioxide in the growth media, which is a completely objective analysis performed by the instrument.

View this table:
  • View inline
  • View popup
TABLE IX

Minimum Detectable Levels by the BacT/ALERT 3D in Biopharmaceutical Samples Inoculated with Different Dilutions of Microorganisms

The average detection time for all microorganisms in the three different types of biopharmaceutical samples studied using the BacT/ALERT® was 1.62 days. Differences between sample types were not significant for six of the 11 microorganisms analyzed. For instance, it took the same average time to detect P. aeruginosa in sWFI, UB, and FB samples. It did not matter that the three samples were derived from different manufacturing processes or that steps or were performed by different analysts on different days. However, B. cepacia, C. albicans, M. radiotolerans, and K. rhizophilla were detected faster in sWFI than in UB and FB samples. When all sample types were combined in all studies, the longest overall detection time was found with M. radiotolerans, 5.77 days, and the fastest with B. subtilis, 0.65 days (Table VI). With the standard method, some of the slow-grow microorganisms such as K. rhizophila and A. niger were very hard to detect by using a visible endpoint to be considered positive. Therefore, an additional day of incubation was needed to obtain a positive visual endpoint. All the three sample types inoculated with B. cepacia showed positive detection by both systems. The average detection time for B. cepacia in all three samples was 1.05 days, while the standard method took 2 days to demonstrate a distinct visual endpoint (Table VI, Figure 3). However, B. cepacia detection in sWFI was faster than in the UB and FB samples. This was very significant because B. cepacia is mostly associated with water contamination during production and processing (6). For M. radiotolerans, the detection times for sWFI samples were significantly faster than in the UB and FB samples (Table VI). Methylobacterium species are known oligotrophic bacteria present in environments with low carbon concentration, which were previously isolated from pharmaceutical manufacturing waters (19). They are slow growers capable of growing on single carbon compounds more reduced than carbon dioxide such as methanol, formaldehyde, and formate, and they demonstrated resistant to chlorine (20, 21). We wanted to see if lowering the carbon concentration in the iFA media will lower the detection time of M. radiotolerans down to the times obtained by the other microorganisms. M. radiotolerans exhibited faster detection time in samples of FB when an equal volume of the iFA media was aseptically replaced with 5 mL or 10 mL of sPBS (Table X). By diluting the media in sPBS the carbon concentration was lowered, allowing the earlier detection in the most diluted sample, for example, 10 mL, by almost a day. The manipulation of the commercial media, for example, iFA, by removing and adding any volume from the bottles prior to testing can increase the risk of analysts contamination during testing. However, these results indicated that media optimization for rapid technologies based upon broth enrichments can enhance the microbial growth in the contaminated samples, leading to faster detection times. Similar results were previously reported using ATP bioluminescence technology by enrichment broths and solid agar media (7, 18).

View this table:
  • View inline
  • View popup
TABLE X

Effect of iFA-Diluted Media on the Detection of Methylobacterium radiotolerans

When the bacteriostasis and fungistasis—the validation test—of the FBP sample A was tested, A. niger and C. albicans showed the longest detection time with the BacT/ALERT® with an average of 2.1 days (Table XI). The fastest detection times were found with B. subtilis with an average of 0.68 days. The FBP sample B showed very similar results, with the longest detection by A. niger, 2.01 days, and again B. subtilis with the fastest, 0.68 days (Table XII).

View this table:
  • View inline
  • View popup
TABLE XI

Bacteriostasis and Fungistasis Testing of Biopharmaceutical Product A Using the BacT/ALERT®

View this table:
  • View inline
  • View popup
TABLE XII

Bacteriostasis and Fungistasis Testing of Biopharmaceutical Product B Using the BacT/ALERT®

These results were very similar to the detection times obtained with the UB, sWFI, and FB samples. The positive control samples exhibited similar detection times when compared to the inoculated samples, indicating that the samples did not have any antimicrobial activity. In general none of the compendial microorganisms tested required more than 3 days to be detected by the system using a single temperature, 33 °C, with agitation. This study confirmed the results reported by Kielpinski et al. (9) demonstrating the feasibility of the BacT/ALERT® system for rapid sterility testing of cell therapy products. They reported the rapid detection of different types of microorganisms in autologous cultured chondrocytes. No interference was found by those samples and the system. Similar results were obtained in this study with a more chemically diverse set of samples. We analyzed four different types of biopharmaceutical samples and did not see any inhibitory effects or interference with the system. All these samples came from different steps in the production, processing, purification, and filling of biopharmaceutical products. Regardless of the sample type, all the microorganisms were detected within 7 days in a reproducible and robust way. There were no differences between analysts in the total detection times for the 11 microorganisms analyzed. If a sample was contaminated, the analysts were able to detect the microbial contaminant regardless of the day of test, sample preparation, inoculum preparation, reagent's lot, inoculum level, etc. If a sample was not contaminated, the analysts did not find any microbial contamination by using either the BacT/ALERT® system, the Steritest™, or the standard TSB and FTM media.

To date the continuous on-line, non-destructive monitoring of biopharmaceutical samples represents the best-case scenario for real-time detection of microbial contamination. The system provided on-line monitoring of the inoculated bottles without any disturbance of the samples. Because the system did not rely on a visual endpoint analysis of the incubated samples, slow-growing microorganisms such as K. rhizophilla and M. radiotolerans can be detected faster than in the standard method without any subjective mistake. Optimization of the sterility testing of biopharmaceutical samples provided rapid on-line, non-destructive detection of microbial contamination during the three processing stages of biopharmaceutical products, UB, FB, and FBP, by eliminating the need of separate incubators and other supportive equipment. Daily readings and manipulations of samples were not needed because the system simultaneously incubated and analyzed the samples for the on-line detection of microbial growth. Faster detection of microbial contamination during the processing stages of a biopharmaceutical product provides a faster response for the implementation of corrective actions, leading to the optimization of process control and manufacturing.

  • © PDA, Inc. 2012

References

  1. 1.↵
    Chapter 71. Sterility Test. United States Pharmacopeia; U.S. Pharmacopeial Convention: Rockville, MD, 2009; pp 2157–2162.
  2. 2.↵
    Chapter 2.6.1. Sterility. European Pharmacopeia; Council of Europe: Strasbourg, France, 2009; pp 155–158.
  3. 3.↵
    1. Moldenhauer J,
    2. Sutton S.
    Towards an improved sterility test. PDA J. Pharm. Sci. Technol. 2004, 58 (6),284–286.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Jimenez L.,
    2. Ignar R.,
    3. D'Aiello R.,
    4. Grech P.
    Use of PCR analysis for sterility testing in pharmaceutical environments. Journal of Rapid Methods & Automation in Microbiology 2000, 8 (1),11–20.
    OpenUrl
  5. 5.↵
    1. Gray J. C.,
    2. Morandell D.,
    3. Gapp G.,
    4. Le Goff N.,
    5. Neuhaus G.,
    6. Staerk A.
    Identification of microorganisms after Milliflex rapid detection—A possibility to identify nonsterile findings in the Milliflex rapid sterility test. PDA J. Pharm. Sci. Technol. 2011, 65 (1),42–54.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Smith R.,
    2. Von Tress M.,
    3. Tubb C.,
    4. Vanhaecke E.
    Evaluation of the ScanRDI as a rapid alternative to the pharmacopoeial sterility test method: comparison of the limits of detection. PDA J. Pharm. Sci. Technol. 2010, 64 (4),356–363.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Gray J. C.,
    2. Staerk A.,
    3. Berchtold M.,
    4. Hecker W.,
    5. Neuhaus G.,
    6. Wirth A.
    Growth-promoting properties of different solid nutrient media evaluated with stressed and unstressed microorganisms: prestudy for the validation of a rapid sterility test. PDA J. Pharm. Sci. Technol. 2010, 64 (3),249–263.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Busey D.,
    2. Tsuji K.
    Bioluminescence for USP sterility testing of pharmaceutical suspension products. Appl. Environ. Microbiol. 1986, 51 (2),349–355.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Kielpinski G.,
    2. Prinzi S.,
    3. Duguid J.,
    4. Du Moulin G.
    Roadmap to approval: use of an automated sterility test method as a lot release for Carticel, autologous cultured chondrocytes. Cytotherapy 2005, 7 (6),531–541.
    OpenUrlPubMed
  10. 10.↵
    Code of Federal Regulations. Electronic records—Electronic signatures. Title 21 Part 11. United States Government, 1997.
  11. 11.↵
    1. Christianson G. G.,
    2. Kosti T. A.
    A comparison of a disposable membrane filtration system with a direct inoculation system for the sterility testing of veterinary biologics. J. Biol. Stand. 1983, 11 (2),83–89.
    OpenUrlPubMed
  12. 12.↵
    PDA Technical Report No. 33. Evaluation, validation, and implementation of new microbiological testing methods. J. Parent. Sci. Technol. 2000, 54 (3).
  13. 13.↵
    Chapter 1223. Validation of Alternative Microbiological Methods. United States Pharmacopeia; U.S. Pharmacopeial Convention: Rockville, MD,2009; pp 731– 733.
  14. 14.↵
    Chapter 5.1.6. Alternative Methods for Control of Microbiological Quality. European Pharmacopeia;Council of Europe:Strasbourg, France,2009; pp 532–543.
  15. 15.↵
    1. Jimenez L.
    Microbial diversity in pharmaceutical product recalls and environments. PDA J. Pharm. Sci. Technol. 2007, 61 (5),383–399.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Baltz R.,
    2. Davies J. E.,
    3. Demain A. L.
    1. Zhang J.
    Chapter 13. Manufacture of Mammalian Cell Biopharmaceuticals. In Manual of Industrial Microbiology and Biotechnology,3rd ed.;Baltz R., Davies J. E., Demain A. L. Eds.; ASM Press: Washington, DC, 2010; pp 179–195.
  17. 17.↵
    1. Verdonk G. P.,
    2. Willemse M. J.,
    3. Hoefs S. G.,
    4. Cremers G.,
    5. van den Heuvel E. R.
    The most probable limit of detection (MPL) for rapid microbiological methods. J. Microbiol. Methods 2010, 82 (3),193–197.
    OpenUrlPubMed
  18. 18.↵
    1. Jimenez L.
    Adenosine triphosphate bioluminescence analysis for rapid screening of microbial contamination in non-sterile pharmaceutical samples. PDA J. Pharm. Sci. Technol. 2004, 58 (3),159–168.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Kawai M.,
    2. Yamagishi J.,
    3. Yamaguchi N.,
    4. Tani K.,
    5. Nasu M.
    Bacterial population dynamics and community structure in a pharmaceutical manufacturing water supply system determined by real-time PCR and PCR-denaturing gradient gel electrophoresis. J. Appl. Microbiol. 2004, 97 (9),1123–1131.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Nishio T.,
    2. Yoshikura T.,
    3. Itoh H.
    Detection of Methylobacterium species by 16S rRNA gene targeted PCR. Appl. Environ. Microbiol. 1998, 63 (4),1594–1597.
    OpenUrl
  21. 21.↵
    1. Knief C.,
    2. Frances L.,
    3. Cantet F.,
    4. Vorholt J. A.
    Cultivation-independent characterization of Methylobacterium populations in the plant phyllosphere by automated ribosomal intergenic spacer analysis. Appl. Environ. Microbiol. 2008, 74 (7),2218–2228.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology: 66 (1)
PDA Journal of Pharmaceutical Science and Technology
Vol. 66, Issue 1
January/February 2012
  • Table of Contents
  • Index by Author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Validation of the BacT/ALERT® 3D System for Rapid Sterility Testing of Biopharmaceutical Samples
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 17 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Validation of the BacT/ALERT® 3D System for Rapid Sterility Testing of Biopharmaceutical Samples
Luis Jimenez, Narendra Rana, Joseph Amalraj, Kimberly Walker, Kasey Travers
PDA Journal of Pharmaceutical Science and Technology Jan 2012, 66 (1) 38-54; DOI: 10.5731/pdajpst.2012.00790

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Validation of the BacT/ALERT® 3D System for Rapid Sterility Testing of Biopharmaceutical Samples
Luis Jimenez, Narendra Rana, Joseph Amalraj, Kimberly Walker, Kasey Travers
PDA Journal of Pharmaceutical Science and Technology Jan 2012, 66 (1) 38-54; DOI: 10.5731/pdajpst.2012.00790
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results and Discussions
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Rapid Sterility Test Systems in the Pharmaceutical Industry: Applying a Structured Approach to Their Evaluation, Validation and Global Implementation
  • Sterility Testing of Injectable Products: Evaluation of the Growth-based BacT/ALERT(R) 3D™ Dual T Culture System
  • Polymerase Chain Reaction/Rapid Methods Are Gaining a Foothold in Developing Countries
  • Google Scholar

More in this TOC Section

  • Mechanical Container Closure Integrity Test: A Method for Cartridge Systems
  • Practical application of setting up an annual Contamination Control Strategy (CCS) assessment
  • A Container Closure Integrity Test Method for Vials Stored at Cryogenic Conditions Using Headspace Oxygen Analysis
Show more Technology/Application

Similar Articles

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2025 PDA Journal of Pharmaceutical Science and Technology Print ISSN: 1079-7440  Digital ISSN: 1948-2124

Powered by HighWire